## **Special Issue**

# Advances in Minimally Invasive Liver Resection for Cancer Therapies

### Message from the Guest Editor

For the initial 30 years after the first report of laparoscopic liver resection (LLR) in 1991, minimally invasive liver resection has been developing rapidly with less invasiveness (especially for patients with deteriorated liver function). Resections in anterolateral segments and left lateral sectionectomy are now common procedures. Partial resection and segmentectomies in posterosuperior segments, repeat LLR and combinations of small anatomical resection and hepatic vein-guided resection are now being established as common generalized approaches that many centers can adapt to common practice. Preoperative simulation and intraoperative navigation with/without anatomical resections are now under investigation. The advantages/disadvantages and indications of robot-assisted liver resection compared to usual LLR should be investigated. Furthermore, reevaluations and discussions of the results from currently performing LLR should be done. This Special Issue of Cancers is dedicated to clarifying the above-listed points with the aim of stimulating further discussion and taking further steps in implementing minimally invasive liver resection as a cancer therapy.

#### **Guest Editor**

Prof. Dr. Zenichi Morise

Department of Surgery, School of Medicine, Fujita Health University Okazaki Medical Center, 1 Gotanda Harisakicho, Okazaki, Aichi 444-0827, Japan

### Deadline for manuscript submissions

closed (1 May 2023)



### **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/110390

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com\_

mdpi.com/journal/cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### **Editor-in-Chief**

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

